# Qualys, Inc.: financial statements, quarterly

QLYS · Nasdaq · CIK 1107843 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/qlys.md) · [Financials](/companies/qlys/financials.md) · [Filings](/companies/qlys/filings.md) · [Insiders](/companies/qlys/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/qlys/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [142](/filings/0001107843-24-000038.md) | [145 d](/filings/0001107843-26-000008.md) | [146](/filings/0001107843-25-000017.md) | [149](/filings/0001107843-25-000031.md) | [154](/filings/0001107843-25-000038.md) | [159 d](/filings/0001107843-26-000008.md) | [160](/filings/0001107843-26-000015.md) | [164](/filings/0001107843-26-000035.md) | [170](/filings/0001107843-25-000038.md) | [175 d](/filings/0001107843-26-000008.md) | [176](/filings/0001107843-26-000015.md) | [182](/filings/0001107843-26-000035.md) |
| Cost of revenue | $m | [26.7](/filings/0001107843-24-000038.md) | [27.1 d](/filings/0001107843-26-000008.md) | [27.2](/filings/0001107843-25-000017.md) | [26.4](/filings/0001107843-25-000031.md) | [28.8](/filings/0001107843-25-000038.md) | [29.0 d](/filings/0001107843-26-000008.md) | [28.9](/filings/0001107843-26-000015.md) | [28.9](/filings/0001107843-26-000035.md) | [27.8](/filings/0001107843-25-000038.md) | [29.2 d](/filings/0001107843-26-000008.md) | [30.0](/filings/0001107843-26-000015.md) | [30.2](/filings/0001107843-26-000035.md) |
| Gross profit | $m | [115](/filings/0001107843-24-000038.md) | [117 d](/filings/0001107843-26-000008.md) | [119](/filings/0001107843-25-000017.md) | [122](/filings/0001107843-25-000031.md) | [125](/filings/0001107843-25-000038.md) | [130 d](/filings/0001107843-26-000008.md) | [131](/filings/0001107843-26-000015.md) | [135](/filings/0001107843-26-000035.md) | [142](/filings/0001107843-25-000038.md) | [146 d](/filings/0001107843-26-000008.md) | [146](/filings/0001107843-26-000015.md) | [152](/filings/0001107843-26-000035.md) |
| Research and development | $m | [27.8](/filings/0001107843-24-000038.md) | [27.5 d](/filings/0001107843-26-000008.md) | [27.5](/filings/0001107843-25-000017.md) | [27.1](/filings/0001107843-25-000031.md) | [28.9](/filings/0001107843-25-000038.md) | [28.3 d](/filings/0001107843-26-000008.md) | [29.2](/filings/0001107843-26-000015.md) | [30.2](/filings/0001107843-26-000035.md) | [28.9](/filings/0001107843-25-000038.md) | [29.0 d](/filings/0001107843-26-000008.md) | [29.0](/filings/0001107843-26-000015.md) | [30.7](/filings/0001107843-26-000035.md) |
| Operating income | $m | [43.6](/filings/0001107843-24-000038.md) | [41.5 d](/filings/0001107843-26-000008.md) | [44.8](/filings/0001107843-25-000017.md) | [48.1](/filings/0001107843-25-000031.md) | [45.0](/filings/0001107843-25-000038.md) | [49.4 d](/filings/0001107843-26-000008.md) | [51.8](/filings/0001107843-26-000015.md) | [51.4](/filings/0001107843-26-000035.md) | [60.0](/filings/0001107843-25-000038.md) | [58.8 d](/filings/0001107843-26-000008.md) | [60.9](/filings/0001107843-26-000015.md) | [61.9](/filings/0001107843-26-000035.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.5](/filings/0001107843-24-000038.md) | [7.0 d](/filings/0001107843-26-000008.md) | [9.8](/filings/0001107843-25-000017.md) | [10.4](/filings/0001107843-25-000031.md) | [6.1](/filings/0001107843-25-000038.md) | [9.9 d](/filings/0001107843-26-000008.md) | [10.8](/filings/0001107843-26-000015.md) | [11.5](/filings/0001107843-26-000035.md) | [14.9](/filings/0001107843-25-000038.md) | [11.3 d](/filings/0001107843-26-000008.md) | [14.3](/filings/0001107843-26-000015.md) | [14.7](/filings/0001107843-26-000035.md) |
| Net income | $m | [46.5](/filings/0001107843-24-000038.md) | [40.6 d](/filings/0001107843-26-000008.md) | [39.7](/filings/0001107843-25-000038.md) | [43.8](/filings/0001107843-25-000038.md) | [46.2](/filings/0001107843-25-000038.md) | [44.0 d](/filings/0001107843-26-000008.md) | [47.5](/filings/0001107843-26-000035.md) | [47.3](/filings/0001107843-26-000035.md) | [50.3](/filings/0001107843-25-000038.md) | [53.2 d](/filings/0001107843-26-000008.md) | [50.6](/filings/0001107843-26-000035.md) | [52.4](/filings/0001107843-26-000035.md) |
| Diluted EPS | $ per share | [1.24](/filings/0001107843-24-000038.md) | not reported | [1.05](/filings/0001107843-25-000017.md) | [1.17](/filings/0001107843-25-000031.md) | [1.24](/filings/0001107843-25-000038.md) | not reported | [1.29](/filings/0001107843-26-000015.md) | [1.29](/filings/0001107843-26-000035.md) | [1.39](/filings/0001107843-25-000038.md) | not reported | [1.42](/filings/0001107843-26-000015.md) | [1.50](/filings/0001107843-26-000035.md) |
| Basic EPS | $ per share | [1.27](/filings/0001107843-24-000038.md) | not reported | [1.08](/filings/0001107843-25-000017.md) | [1.19](/filings/0001107843-25-000031.md) | [1.26](/filings/0001107843-25-000038.md) | not reported | [1.30](/filings/0001107843-26-000015.md) | [1.30](/filings/0001107843-26-000035.md) | [1.40](/filings/0001107843-25-000038.md) | not reported | [1.42](/filings/0001107843-26-000015.md) | [1.50](/filings/0001107843-26-000035.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [209](/filings/0001107843-23-000007.md) | [204](/filings/0001107843-25-000009.md) | [274](/filings/0001107843-24-000016.md) | [281](/filings/0001107843-24-000028.md) | [235](/filings/0001107843-24-000038.md) | [232](/filings/0001107843-26-000008.md) | [291](/filings/0001107843-25-000017.md) | [194](/filings/0001107843-25-000031.md) | [225](/filings/0001107843-25-000038.md) | [250](/filings/0001107843-26-000035.md) | [279](/filings/0001107843-26-000015.md) | [250](/filings/0001107843-26-000035.md) |
| Current assets | $m | [562](/filings/0001107843-23-000007.md) | [600](/filings/0001107843-25-000009.md) | [605](/filings/0001107843-24-000016.md) | [534](/filings/0001107843-24-000028.md) | [537](/filings/0001107843-24-000038.md) | [586](/filings/0001107843-26-000008.md) | [602](/filings/0001107843-25-000017.md) | [543](/filings/0001107843-25-000031.md) | [597](/filings/0001107843-25-000038.md) | [658](/filings/0001107843-26-000035.md) | [657](/filings/0001107843-26-000015.md) | [619](/filings/0001107843-26-000035.md) |
| Total assets | $m | [752](/filings/0001107843-23-000007.md) | [813](/filings/0001107843-25-000009.md) | [862](/filings/0001107843-24-000016.md) | [877](/filings/0001107843-24-000028.md) | [908](/filings/0001107843-24-000038.md) | [974](/filings/0001107843-26-000008.md) | [996](/filings/0001107843-25-000017.md) | [1,000](/filings/0001107843-25-000031.md) | [1,032](/filings/0001107843-25-000038.md) | [1,095](/filings/0001107843-26-000035.md) | [1,095](/filings/0001107843-26-000015.md) | [1,074](/filings/0001107843-26-000035.md) |
| Current liabilities | $m | [370](/filings/0001107843-23-000007.md) | [389](/filings/0001107843-25-000009.md) | [391](/filings/0001107843-24-000016.md) | [372](/filings/0001107843-24-000028.md) | [389](/filings/0001107843-24-000038.md) | [428](/filings/0001107843-26-000008.md) | [432](/filings/0001107843-25-000017.md) | [417](/filings/0001107843-25-000031.md) | [432](/filings/0001107843-25-000038.md) | [467](/filings/0001107843-26-000035.md) | [459](/filings/0001107843-26-000015.md) | [447](/filings/0001107843-26-000035.md) |
| Total liabilities | $m | [429](/filings/0001107843-23-000007.md) | [444](/filings/0001107843-25-000009.md) | [458](/filings/0001107843-24-000016.md) | [449](/filings/0001107843-24-000028.md) | [459](/filings/0001107843-24-000038.md) | [496](/filings/0001107843-26-000008.md) | [498](/filings/0001107843-25-000017.md) | [491](/filings/0001107843-25-000031.md) | [503](/filings/0001107843-25-000038.md) | [534](/filings/0001107843-26-000035.md) | [525](/filings/0001107843-26-000015.md) | [512](/filings/0001107843-26-000035.md) |
| Shareholders' equity | $m | [323](/filings/0001107843-24-000038.md) | [368](/filings/0001107843-26-000008.md) | [404](/filings/0001107843-25-000038.md) | [428](/filings/0001107843-25-000038.md) | [450](/filings/0001107843-25-000038.md) | [477](/filings/0001107843-26-000035.md) | [498](/filings/0001107843-26-000035.md) | [508](/filings/0001107843-26-000035.md) | [529](/filings/0001107843-25-000038.md) | [561](/filings/0001107843-26-000035.md) | [570](/filings/0001107843-26-000035.md) | [562](/filings/0001107843-26-000035.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [92.4 d](/filings/0001107843-24-000038.md) | [33.8 d](/filings/0001107843-26-000008.md) | [85.5](/filings/0001107843-25-000017.md) | [49.8 d](/filings/0001107843-25-000031.md) | [61.0 d](/filings/0001107843-25-000038.md) | [47.7 d](/filings/0001107843-26-000008.md) | [110](/filings/0001107843-26-000015.md) | [33.8 d](/filings/0001107843-26-000035.md) | [90.4 d](/filings/0001107843-25-000038.md) | [75.7 d](/filings/0001107843-26-000008.md) | [95.3](/filings/0001107843-26-000015.md) | [59.6 d](/filings/0001107843-26-000035.md) |
| Capital expenditure | $m | [1.8 d](/filings/0001107843-24-000038.md) | [1.5 d](/filings/0001107843-26-000008.md) | [2.1](/filings/0001107843-25-000017.md) | [1.0 d](/filings/0001107843-25-000031.md) | [3.4 d](/filings/0001107843-25-000038.md) | [5.8 d](/filings/0001107843-26-000008.md) | [2.0](/filings/0001107843-26-000015.md) | [1.3 d](/filings/0001107843-26-000035.md) | [0.9 d](/filings/0001107843-25-000038.md) | [0.7 d](/filings/0001107843-26-000008.md) | [1.7](/filings/0001107843-26-000015.md) | [3.7 d](/filings/0001107843-26-000035.md) |
| Share repurchases | $m | [38.9 d](/filings/0001107843-24-000038.md) | [23.1 d](/filings/0001107843-26-000008.md) | [18.0](/filings/0001107843-25-000017.md) | [35.0 d](/filings/0001107843-25-000031.md) | [44.2 d](/filings/0001107843-25-000038.md) | [42.7 d](/filings/0001107843-26-000008.md) | [39.7](/filings/0001107843-26-000015.md) | [49.9 d](/filings/0001107843-26-000035.md) | [49.2 d](/filings/0001107843-25-000038.md) | [44.7 d](/filings/0001107843-26-000008.md) | [53.5](/filings/0001107843-26-000015.md) | [77.9 d](/filings/0001107843-26-000035.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.2](/filings/0001107843-23-000007.md) | [37.7](/filings/0001107843-24-000016.md) | [37.4](/filings/0001107843-24-000028.md) | [37.4](/filings/0001107843-24-000038.md) | [37.7](/filings/0001107843-25-000017.md) | [37.5](/filings/0001107843-25-000031.md) | [37.1](/filings/0001107843-25-000038.md) | [36.8](/filings/0001107843-26-000015.md) | [36.5](/filings/0001107843-26-000035.md) | [36.3](/filings/0001107843-25-000038.md) | [35.7](/filings/0001107843-26-000015.md) | [35.0](/filings/0001107843-26-000035.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 34,595,001 at 2026-07-22, from the cover of the [10-Q filed 2026-08-04](/filings/0001107843-26-000035.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:33 ET. No prices; not investment advice.